Biomea Fusion to present Icovamenib data highlighting durable T2D Control at ADA 2025
Biomea Fusion, a clinical-stage diabetes and obesity medicines company, announced the presentation of new preclinical and clinical data for icovamenib, the company’s investigational oral menin inhibitor, at the… read more.
